Evidence map›Paper›PMID 32364673›Full record

ArticleThoracic cancer2020

microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.

Weizhong Han, Xiaoxia Ren, Yupeng Yang, Haixia Li, Lin Zhao, Zhaoxia Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. The role of HOXA1 in cancer and targeted therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Weizhong HanDepartment of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaoxia RenDepartment of Cardiothoracic Surgey, Yantaishan Hospital, Yantai, China.
Yupeng YangDepartment of General Surgery, Jinan Zhangqiu District Hospital of TCM, Jinan, China.
Haixia LiDepartment of Anesthesiology, The People's Hospital of Zhangqiu Area, Jinan, China.
Lin ZhaoDepartment of Respiratory Medicine, People's Hospital of Rizhao, Rizhao, China.
Zhaoxia LinDepartment of Clinical Laboratory, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.ORCID 0000-0002-6107-5343
Zhangqiu City People's Hospital · CNPeople’s Hospital of Rizhao · CNQingdao University · CNShandong University · CNYantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is a leading subtype in lung cancer, with high morbidities and mortalities worldwide. microRNA (miRNA) has appeared to play indispensable roles in a variety of solid carcinomas. The current study focused on the functions of miR-100 in NSCLC.

methodsqRT-PCR was performed to detect miR-100 and HOXA1 expressions in NSCLC tissues and cells. MTT and transwell assays were used to determine the functions of miR-100 in NSCLC cell proliferation, invasion and migration abilities. Western blot was used to measure related protein expressions.

resultsqRT-PCR results showed that miR-100 expressions were dramatically decreased in NSCLC tissues. MTT assays indicated that miR-100 restoration inhibited NSCLC cell proliferation. Furthermore, transwell assay was performed to determine the impacts of miR-100 on NSCLC invasion and migration abilities. As expected, the invasion and migration capacities were significantly repressed. Direct interactions between HOXA1 and miR-100 were also verified via dual-luciferase reporter assays. Western blot analysis demonstrated that miR-100 exerted suppressive functions via regulating EMT and Wnt/β-catenin in NSCLC cells.

conclusionsOur results showed that miR-100 served antitumor roles in NSCLC, providing new evidence of miR-100 as a promising therapeutic biomarker in NSCLC.

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinoma of LungAnimalsApoptosisbeta CateninBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleHomeobox A1 ProteinHomeodomain ProteinsHumansLung Neoplasmsbeta CateninBiomarkers, TumorCTNNB1 protein, humanHomeobox A1 ProteinHomeodomain ProteinsMicroRNAsMIRN100 microRNA, humanTranscription FactorsTumor Suppressor ProteinsWnt1 ProteinWNT1 protein, humanEpithelial-mesenchymal transitionHOXA1miR-100non-small cell lung cancerWnt/β-catenin

Identifiers

PMID32364673
PMCPMC7262897
OpenAlexW3021112723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.